A citation-based method for searching scientific literature

Ion Cristóbal, Francisco J Blanco, Laura Garcia-Orti, Nerea Marcotegui, Carmen Vicente, José Rifon, Francisco J Novo, Eva Bandres, María J Calasanz, Carmelo Bernabeu, María D Odero. Blood 2010
Times Cited: 107







List of co-cited articles
722 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.
Rocco Piazza, Simona Valletta, Nils Winkelmann, Sara Redaelli, Roberta Spinelli, Alessandra Pirola, Laura Antolini, Luca Mologni, Carla Donadoni, Elli Papaemmanuil,[...]. Nat Genet 2013
242
54

Somatic SETBP1 mutations in myeloid malignancies.
Hideki Makishima, Kenichi Yoshida, Nhu Nguyen, Bartlomiej Przychodzen, Masashi Sanada, Yusuke Okuno, Kwok Peng Ng, Kristbjorn O Gudmundsson, Bandana A Vishwakarma, Andres Jerez,[...]. Nat Genet 2013
171
34

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
I Cristóbal, L Garcia-Orti, C Cirauqui, M M Alonso, M J Calasanz, M D Odero. Leukemia 2011
97
31

De novo mutations of SETBP1 cause Schinzel-Giedion syndrome.
Alexander Hoischen, Bregje W M van Bon, Christian Gilissen, Peer Arts, Bart van Lier, Marloes Steehouwer, Petra de Vries, Rick de Reuver, Nienke Wieskamp, Geert Mortier,[...]. Nat Genet 2010
321
30

Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10.
Kevin Oakley, Yufen Han, Bandana A Vishwakarma, Su Chu, Ravi Bhatia, Kristbjorn O Gudmundsson, Jonathan Keller, Xiongfong Chen, Vasyl Vasko, Nancy A Jenkins,[...]. Blood 2012
49
55

Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET.
M Minakuchi, N Kakazu, M J Gorrin-Rivas, T Abe, T D Copeland, K Ueda, Y Adachi. Eur J Biochem 2001
58
44

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.
F Damm, R Itzykson, O Kosmider, N Droin, A Renneville, V Chesnais, V Gelsi-Boyer, S de Botton, N Vey, C Preudhomme,[...]. Leukemia 2013
86
30

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
M Meggendorfer, U Bacher, T Alpermann, C Haferlach, W Kern, C Gambacorti-Passerini, T Haferlach, S Schnittger. Leukemia 2013
112
24

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Paolo Neviani, Ramasamy Santhanam, Rossana Trotta, Mario Notari, Bradley W Blaser, Shujun Liu, Hsiaoyin Mao, Ji Suk Chang, Annamaria Galietta, Ashwin Uttam,[...]. Cancer Cell 2005
368
23

Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Hirotoshi Sakaguchi, Yusuke Okuno, Hideki Muramatsu, Kenichi Yoshida, Yuichi Shiraishi, Mariko Takahashi, Ayana Kon, Masashi Sanada, Kenichi Chiba, Hiroko Tanaka,[...]. Nat Genet 2013
149
18

CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
A Pardanani, T L Lasho, R R Laborde, M Elliott, C A Hanson, R A Knudson, R P Ketterling, J E Maxson, J W Tyner, A Tefferi. Leukemia 2013
158
17

SETBP1 mutation analysis in 944 patients with MDS and AML.
F Thol, K J Suchanek, C Koenecke, M Stadler, U Platzbecker, C Thiede, T Schroeder, G Kobbe, S Kade, P Löffeld,[...]. Leukemia 2013
53
30

Protein phosphatase 2A: a target for anticancer therapy.
Danilo Perrotti, Paolo Neviani. Lancet Oncol 2013
257
16

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Paolo Neviani, Ramasamy Santhanam, Joshua J Oaks, Anna M Eiring, Mario Notari, Bradley W Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Carlo Gambacorti-Passerini,[...]. J Clin Invest 2007
274
15

Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12).
Ioannis Panagopoulos, Gitte Kerndrup, Niels Carlsen, Bodil Strömbeck, Margareth Isaksson, Bertil Johansson. Br J Haematol 2007
34
44

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML.
R R Laborde, M M Patnaik, T L Lasho, C M Finke, C A Hanson, R A Knudson, R P Ketterling, A Pardanani, A Tefferi. Leukemia 2013
68
22

Frequent pathway mutations of splicing machinery in myelodysplasia.
Kenichi Yoshida, Masashi Sanada, Yuichi Shiraishi, Daniel Nowak, Yasunobu Nagata, Ryo Yamamoto, Yusuke Sato, Aiko Sato-Otsubo, Ayana Kon, Masao Nagasaki,[...]. Nature 2011
15

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.
Julia E Maxson, Jason Gotlib, Daniel A Pollyea, Angela G Fleischman, Anupriya Agarwal, Christopher A Eide, Daniel Bottomly, Beth Wilmot, Shannon K McWeeney, Cristina E Tognon,[...]. N Engl J Med 2013
319
15

Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
C H Switzer, R Y S Cheng, T M Vitek, D J Christensen, D A Wink, M P Vitek. Oncogene 2011
117
14

CIP2A inhibits PP2A in human malignancies.
Melissa R Junttila, Pietri Puustinen, Minna Niemelä, Raija Ahola, Hugh Arnold, Trine Böttzauw, Risto Ala-aho, Christina Nielsen, Johanna Ivaska, Yoichi Taya,[...]. Cell 2007
444
14


Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.
Ion Cristóbal, Laura Garcia-Orti, Cristina Cirauqui, Xabier Cortes-Lavaud, María A García-Sánchez, María J Calasanz, María D Odero. Haematologica 2012
81
16

Protein phosphatase 2A regulatory subunits and cancer.
Pieter J A Eichhorn, Menno P Creyghton, René Bernards. Biochim Biophys Acta 2009
369
12

Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.
Kathryn G Roberts, Amanda M Smith, Fiona McDougall, Helen Carpenter, Martin Horan, Paolo Neviani, Jason A Powell, Daniel Thomas, Mark A Guthridge, Danilo Perrotti,[...]. Cancer Res 2010
100
12

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.
Dale J Christensen, Youwei Chen, Jessica Oddo, Karen M Matta, Jessica Neil, Evan D Davis, Alicia D Volkheimer, Mark C Lanasa, Daphne R Friedman, Barbara K Goodman,[...]. Blood 2011
89
13


Multiple pathways regulated by the tumor suppressor PP2A in transformation.
Jukka Westermarck, William C Hahn. Trends Mol Med 2008
259
11


Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias.
Danilo Perrotti, Paolo Neviani. Cancer Metastasis Rev 2008
94
11


Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation.
Yan Yang, Qing Huang, Yanjun Lu, Xiaoqing Li, Shiang Huang. J Cell Biochem 2012
55
20

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Sahar A Saddoughi, Salih Gencer, Yuri K Peterson, Katherine E Ward, Archana Mukhopadhyay, Joshua Oaks, Jacek Bielawski, Zdzislaw M Szulc, Raquela J Thomas, Shanmugam P Selvam,[...]. EMBO Mol Med 2013
169
11

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Anupriya Agarwal, Ryan J MacKenzie, Raffaella Pippa, Christopher A Eide, Jessica Oddo, Jeffrey W Tyner, Rosalie Sears, Michael P Vitek, María D Odero, Dale J Christensen,[...]. Clin Cancer Res 2014
85
12

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
Timothy J Ley, Christopher Miller, Li Ding, Benjamin J Raphael, Andrew J Mungall, A Gordon Robertson, Katherine Hoadley, Timothy J Triche, Peter W Laird, Jack D Baty,[...]. N Engl J Med 2013
11

SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
D Inoue, J Kitaura, H Matsui, H-A Hou, W-C Chou, A Nagamachi, K C Kawabata, K Togami, R Nagase, S Horikawa,[...]. Leukemia 2015
47
23

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
11

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
James W Vardiman, Jüergen Thiele, Daniel A Arber, Richard D Brunning, Michael J Borowitz, Anna Porwit, Nancy Lee Harris, Michelle M Le Beau, Eva Hellström-Lindberg, Ayalew Tefferi,[...]. Blood 2009
10

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression.
Claire M Lucas, Robert J Harris, Athina Giannoudis, Mhairi Copland, Joseph R Slupsky, Richard E Clark. Blood 2011
103
10


Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hsin-An Hou, Yuan-Yeh Kuo, Jih-Luh Tang, Wen-Chien Chou, Ming Yao, Yan-Jun Lai, Chien-Chin Lin, Chien-Yuan Chen, Chieh-Yu Liu, Mei-Hsuan Tseng,[...]. Am J Hematol 2014
48
20

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.
Marta Fernandez-Mercado, Andrea Pellagatti, Cristina Di Genua, Maria Jose Larrayoz, Nils Winkelmann, Paula Aranaz, Adam Burns, Anna Schuh, Maria Jose Calasanz, Nicholas C P Cross,[...]. Br J Haematol 2013
33
30

Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development.
B A Vishwakarma, N Nguyen, H Makishima, N Hosono, K O Gudmundsson, V Negi, K Oakley, Y Han, B Przychodzen, J P Maciejewski,[...]. Leukemia 2016
19
52


PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Paolo Neviani, Jason G Harb, Joshua J Oaks, Ramasamy Santhanam, Christopher J Walker, Justin J Ellis, Gregory Ferenchak, Adrienne M Dorrance, Carolyn A Paisie, Anna M Eiring,[...]. J Clin Invest 2013
150
9

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Sa A Wang, Robert P Hasserjian, Patricia S Fox, Heesun J Rogers, Julia T Geyer, Devon Chabot-Richards, Elizabeth Weinzierl, Joseph Hatem, Jesse Jaso, Rashmi Kanagal-Shamanna,[...]. Blood 2014
109
9

Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.
R Pippa, A Dominguez, D J Christensen, I Moreno-Miralles, M J Blanco-Prieto, M P Vitek, M D Odero. Leukemia 2014
36
25

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.
Kim-Hien T Dao, Magdolna B Solti, Julia E Maxson, Elliott F Winton, Richard D Press, Brian J Druker, Jeffrey W Tyner. Leuk Res Rep 2014
54
16

Myb expression is critical for myeloid leukemia development induced by Setbp1 activation.
Nhu Nguyen, Bandana A Vishwakarma, Kevin Oakley, Yufen Han, Bartlomiej Przychodzen, Jaroslaw P Maciejewski, Yang Du. Oncotarget 2016
14
64

Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.
Rocio Acuna-Hidalgo, Pelagia Deriziotis, Marloes Steehouwer, Christian Gilissen, Sarah A Graham, Sipko van Dam, Julie Hoover-Fong, Aida B Telegrafi, Anne Destree, Robert Smigiel,[...]. PLoS Genet 2017
17
52

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching-Shih Chen, James T Dalton,[...]. Blood 2008
125
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.